CT-95 in Advanced Cancers Associated With Mesothelin Expression

Phase 1a Dose Escalation: Participants with ovarian epithelial tumors, primary peritoneal

or fallopian tube cancer (PROC), epithelioid mesothelioma, lung adenocarcinoma,

pancreatic adenocarcinoma, colorectal cancer, cholangiocarcinoma, and gastric/GEJ

adenocarcinomas will be enrolled in one of approximately 9 dose escalation cohorts to

assess the safety and tolerability of CT-95, as well as determine the maximum tolerated

dose (MTD) or other recommended dose(s) for expansion (RDE[s]) for further dose expansion

cohorts.

Participants will receive CT-95 as a single agent administered once weekly (QW)

intravenously (IV) over a 4-week cycle.

Phase 1b Dose Expansion: The RDE(s) of CT-95 determined in Phase 1a will be evaluated in

2-4 indication-specific expansion cohorts of up to 20 subjects each (i.e. up to 80

participants total). Different indications, dose levels, and/or schedules may be

explored. The expansion doses and/or dosing schedules for Phase 1b will be determined by

Sponsor in conjunction with SRC based upon all available safety, PK, PD, biomarker, and

preliminary efficacy data from Phase 1a.